



Soo Lim

Seoul National University, Korea

Education

Period	Affiliation	Position
– 2006-2009	Seoul National University School of Public Health	Doctor of Public Health
– 2004-2006	Seoul National University College of Medicine	Ph.D.
– 2002-2004	Seoul National University School of Public Health	M.Sc.
– 1990-1996	Seoul National University College of Medicine	M.D.

Affiliations / Experience

Period	Affiliation	Position
– 2017-Present	Endocrinology Seoul National University Bundang Hospital	Professor
– 2011-2012	Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA	Research fellow
– 2005-2017	Endocrinology Seoul National University Bundang Hospital	Associate Professor
– 2001-2004	Department of Quarantine National Institute of Health, Korea	Epidemiology Intelligence Service Officer
– 1997-2001	Internal Medicine Seoul National University Bundang Hospital	Resident

Committee Memberships

- American Diabetes Association
- Korean Diabetes Association
- Korean Society of Endocrinology
- Korean Society of Lipidology and Atherosclerosis

Publications

- Sohn M, Nam S, Nauck MA, Lim S. Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes. *BMC Med.* 2024 Jul 2;22(1):273. doi: 10.1186/s12916-024-03483-z. PMID: 38956548; PMCID: PMC11218058
- Cho YK, Kim KS, Lee BW, Hong JH, Yu JM, Lim S, Kim YA, Lee CB, Kim SS, Kwak SH, Lee WJ. Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-Controlled Study. *Clin Ther.* 2024 Jul 26:S0149-2918(24)00198-X. doi: 10.1016/j.clinthera.2024.06.023. Epub ahead of print. PMID: 39068060
- Lee, Yong-Ho & MIN, KYUNGWAN & Hong, Jun Hwa & Lim, Soo & YU, JAEMYUNG & Chung, Choon & Moon, Jun Sung & Won, Jong Chul & AHN, CHUL & LEE, JIE-EUN & Kim, Tae & LEE, BYUNG-WAN. (2024). 853-P: Efficacy and Safety of HD-6277, a Novel GPR40 Agonist, in Patients with Type 2 Diabetes—A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Trial. *Diabetes.* 73. 10.2337/db24-853-P
- Kim NH, Moon JS, Lee YH, Cho HC, Kwak SH, Lim S, Moon MK, Kim DL, Kim TH, Ko E, Lee J, Kim SG. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial. *Diabetes Obes Metab.* 2024 Sep;26(9):3642-3652. doi: 10.1111/dom.15705. Epub 2024 Jun 10. PMID: 38853720
- Lim S, Sohn M, Nauck MA. Cardiovascular outcome with SGLT2i and GLP1RA. *Eur J Intern Med.* 2024 Jun 6:S0953-6205(24)00235-8. doi: 10.1016/j.ejim.2024.05.030. Epub ahead of print. PMID: 38849275